Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...
This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...
Protein kinase research presents an opportunity to explore molecular targets in the body to treat diseases like cancer and ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...
Powered Presicion Drug Design HANGZHOU, China and LONDON, March 07, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage ...
Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...
A new study has described a potential mechanism that could help explain why some proteins refold in a different pattern than ...
A recent study from Western University has found that a natural compound found in sweet oranges and tangerines, called ...
The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...